Evaluation of a potential human infection model of yellow fever using live attenuated yellow fever vaccine

Evaluation of a potential human infection model of yellow fever using live attenuated yellow fever vaccine - YF INFECT

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON54831

Enrollment

Registered

2020-01-28

Start date

2023-02-17

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

viral infection Yellow fever

Interventions

All volunteers will undergo vaccination once with the yellow fever vaccine Stamaril

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers aged 18-50 years

Exclusion criteria

Exclusion criteria: Previous yellow fever vaccination, primary or secondary immunedeficiency, thymus dysfunction (thymoma, thymectomy, thymus radiation, myastenia gravis, DiGeorge syndrome), multipe sclerosis, pregnancy, chicken egg allergy, previous allergic reaction to a compound present in the yellow fever vaccine, previous vaccination with another live-attenuated vaccine within a period of 4 weeks

Design outcomes

Primary

Measure	Time frame
Primary end point: 1. Percentage of participants with measurable viruria (yellow fever vaccine virus measurable in the urine) after yellow fever vaccination 2. Peak of viruria after yellow fever vaccination	—

Secondary

Measure	Time frame
1. Hight of viruria 2. Hight of antibody titers 3. Hight if viremia 4. Analysis of the innate immune response to yellow fever vaccine	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)